Host: |
Rabbit |
Applications: |
WB/IHC/IF/ELISA |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-Fanconi anemia group D2 protein (188-237 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
Concentration: |
1 mg/mL |
Dilution Range: |
WB 1:500-1:2000IHC 1:100-1:300ELISA 1:10000IF 1:50-200 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
FANCD2 |
Gene ID: |
2177 |
Uniprot ID: |
FACD2_HUMAN |
Immunogen Region: |
188-237 aa |
Specificity: |
FANCD2 Polyclonal Antibody detects endogenous levels of FANCD2 protein. |
Immunogen: |
The antiserum was produced against synthesized peptide derived from the human FANCD2 at the amino acid range 188-237 |
Post Translational Modifications | Monoubiquitinated on Lys-561 during S phase and upon genotoxic stress by FANCL in complex with E2 ligases UBE2T or UBE2W (isoform 1 and isoform 2). Deubiquitinated by USP1 as cells enter G2/M, or once DNA repair is completed. Monoubiquitination requires the joint intervention of the FANC core complex, including FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCM, and proteins involved in cell cycle checkpoints and DNA repair, including RPA1, ATR, CHEK1 and BRCA1, and is mediated by FANCL/PHF9. Ubiquitination is required for binding to chromatin, interaction with BRCA1, BRCA2 and MTMR15/FAN1, DNA repair, and normal cell cycle progression, but not for phosphorylation on Ser-222 or interaction with MEN1. Phosphorylated in response to various genotoxic stresses by ATM and/or ATR. Upon ionizing radiation, phosphorylated by ATM on Ser-222 and Ser-1404. Phosphorylation on Ser-222 is required for S-phase checkpoint activation, but not for ubiquitination, foci formation, or DNA repair. In contrast, phosphorylation by ATR on other sites may be required for ubiquitination and foci formation. |
Function | Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching. |
Protein Name | Fanconi Anemia Group D2 ProteinProtein Facd2 |
Database Links | Reactome: R-HSA-6783310Reactome: R-HSA-6796648 |
Cellular Localisation | NucleusConcentrates In Nuclear Foci During S Phase And Upon Genotoxic StressAt The Onset Of MitosisExcluded From Chromosomes And Diffuses Into The CytoplasmReturning To The Nucleus At The End Of Cell DivisionObserved In A Few Spots Localized In Pairs On The Sister Chromatids Of Mitotic Chromosome Arms And Not CentromeresOne On Each ChromatidsThese Foci Coincide With Common Fragile Sites And Could Be Sites Of Replication Fork StallingThe Foci Are Frequently Interlinked Through Blm-Associated Ultra-Fine Dna BridgesFollowing Aphidicolin TreatmentTargets Chromatid Gaps And Breaks |
Alternative Antibody Names | Anti-Fanconi Anemia Group D2 Protein antibodyAnti-Protein Facd2 antibodyAnti-FANCD2 antibodyAnti-FACD antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance